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Abstract Functional analyses were performed with microsomal
human 11L-hydroxysteroid dehydrogenase type 1 overexpressed
in the yeast Pichia pastoris. Cell extracts or microsomes from
transformed strains displayed dehydrogenase and reductase
activities, which were up to 10 times higher than in human liver
microsomes, while for whole cells cortisone reduction but no
dehydrogenase activity was observed. The synthetic glucocorti-
coids prednisolone and prednisone were efficiently metabolized
by subcellular fractions, whereas no activity was observed with
dexamethasone, budesonide and deflazacort. Inhibitors found to
be effective towards the recombinant 11L-hydroxysteroid dehy-
drogenase include synthetic steroids and xenobiotic compounds,
revealing selective inhibition of the reaction direction, useful for
development of specific inhibitors.
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1. Introduction
Glucocorticoid (GC) hormone action is achieved by speci¢c
intracellular hormone receptors acting on DNA response ele-
ments thereby regulating repression or enhancement of gene
transcription [1,2]. The enzyme 11L-hydroxysteroid dehydro-
genase (EC 1.1.1.146, 11L-HSD) plays an important role in
this concept by catalyzing the interconversion between the GC
receptor ligand (cortisol in humans) and the non-binding de-
hydro product (cortisone in humans). 11L-HSD therefore con-
stitutes the major factor in a prereceptor hormone control
mechanism [3,4].
Thus far, two di¡erent 11L-hydroxysteroid dehydrogenase
forms have been characterized at the molecular level, although
further forms are also likely to exist [4,5]. The two known
isozymes belong to the short-chain dehydrogenases/reductases
(SDR) superfamily [6], are microsomal enzymes, display a
mutually exclusive cellular expression pattern, and di¡er in
kinetic properties. Type 1 11L-hydroxysteroid dehydrogenase
(11L-HSD-1) was ¢rst isolated from liver, but has a wide-
spread central nervous and peripheral tissue distribution pat-
tern. It is a bidirectional enzyme which in vivo functions
mainly as a reductase, thereby converting circulating cortisone
to the ‘receptor active’ cortisol hormone [3,4,7^9], which is
essential in hepatic and adipose tissue carbohydrate metabo-
lism [9]. The type 2 form (11L-HSD-2), however, is in vivo a
unidirectional enzyme and exclusively functions as a NAD
dependent dehydrogenase of adrenal glucocorticoids, convert-
ing cortisol to its inactive congener, hence ‘protecting’ the
mineralocorticoid receptor against occupancy of cortisol
[10,11]. In this paper we report overexpression of 11L-HSD-
1 in yeast and describe its functional and kinetic properties.
2. Materials and methods
2.1. Materials
Steroids, naringenin and furosemide were obtained from Sigma,
de£azacort from Hoechst, 22-R/S budesonide epimers and its 11-
oxo metabolites from Astra Draco.
2.2. Cloning of human 11L-HSD-1
Human 11L-hydroxysteroid dehydrogenase type 1A cDNA was ob-
tained by RT-PCR of a total RNA preparation from a liver trans-
plantation sample. RT-PCR was carried out using primers speci¢c for
the human type 1A sequence [8]. The resulting product was ligated
into the SnaBI/NotI restriction sites of the pPIC3.5 vector (Invitro-
gen). The sequence of the construct obtained was veri¢ed by auto-
mated DNA sequencing.
2.3. Yeast transformation, selection and overexpression
After linearization of the plasmid DNA with endonucleases BglII or
SacI, yeast strains KM71 or GS115 were transformed using the
spheroplasting method [12]. After homologous recombination of the
11L-HSD-1 DNA into the Pichia alcohol oxidase (AOX1) locus, the
obtained clones were selected by phenotyping for HisMut and
HisMuts transformants. Recombinant strains were con¢rmed by
PCR of genomic DNA with gene speci¢c primers. Positive clones
for each phenotype were subjected to expression trials. To exclude
intrinsic activities, mock-transformed strains (vector alone, no insert)
were used as background controls. Yeast clones were grown at 30‡C
for 3^5 days in bu¡ered complex medium (1% yeast extract, 2% pep-
tone, 100 mM potassium phosphate, pH 6.0, 1.34% yeast nitrogen
base, 4U1035% biotin) containing 0.5% (v/v) methanol for induction.
2.4. Analysis of glucocorticoid metabolism in whole Pichia pastoris cells
106 cells of a 3 day culture were grown for 60 min in bu¡ered
complex methanol medium containing di¡erent concentrations of cor-
tisol or cortisone, ranging from 5 to 500 Wmol/l. After separation of
cells, the medium was extracted twice with ethyl acetate/acetic acid
(99:1, v/v), the organic phase was blown down by nitrogen, and the
residue was dissolved in RP-HPLC eluent and analyzed as described
below.
2.5. Preparation of subcellular fraction
Yeast subcellular fractions were prepared by mechanically disrupt-
ing the washed cells with glass beads (Sigma, 245^400 Wm) in 20 mM
sodium phosphate bu¡er, 5% glycerol, 1 mM EDTA, pH 7.0, con-
taining 1 mM PMSF. After removal of cell debris by low speed cen-
trifugation, an S9 fraction was prepared by centrifugation for 15 min
at 9000Ug. A ¢nal microsomal pellet was obtained by PEG 4000/
NaCl precipitation or by ultracentrifugation at 100 000Ug of the S9
fraction for 1 h. Microsomes were resuspended in 40 mM sodium
phosphate, 1 mM EDTA, 5% glycerol, pH 7.5, to a protein concen-
tration of 1^5 mg/ml. The liver samples were homogenized in 4-fold
volumes of ice-cold bu¡er (40 mM Tris-HCl, pH 7.5, 1 mM EDTA,
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1 mM DTT, 5% sucrose). The microsomal fraction was obtained after
centrifugation of the S9 fraction for 60 min at 100 000Ug.
2.6. Enzymatic assays and data analysis
Microsomal or S9 fractions were incubated at 37‡C for 10^60 min
in a reaction mixture containing 0.5 mM coenzyme (NADP or
NADPH), 1^100 WM steroid substrate, 10^20 Wg protein, in 100
mM Tris-HCl, pH 7.4. Inhibitors were used at concentrations ranging
from 0.05 to 500 WM. Reactions were stopped by addition of a 3-fold
excess of acetonitrile and centrifugation for 5 min. The obtained
supernatants were analyzed by RP-HPLC on a C18 stationary phase
with an eluent of 30% acetonitrile in 0.1% ammonium acetate, pH 7.0.
UV detection of metabolites was achieved at 240 nm. Kinetic con-
stants were calculated using the Enzpack for Windows software (Bio-
soft, Cambridge, UK). Protein concentrations of samples were deter-
mined using the Lowry method with bovine serum albumin as
standard.
3. Results
3.1. Cloning and expression of human 11L-HSD-1 in
P. pastoris
The human hepatic 11L-HSD-1 was cloned into the expres-
sion plasmid pPIC3.5, transformed into P. pastoris strains
GS115 and KM71, and clones expressing recombinant protein
were selected.
3.2. Speci¢c activities in liver and yeast microsomes
Yeast microsomal activities were about 8^10-fold higher
than those of human liver microsomes, which is the tissue
with the highest in vivo speci¢c activity (Table 1). This indi-
cates successful overexpression of the human gene in P. pas-
toris. However, whereas an enrichment in speci¢c activity of
the oxidative reaction is achieved during microsome prepara-
tion from the S9 fraction (5.6^16.6 nmol/minUmg, with an
average recovery of 92^97%), a loss in the speci¢c activity of
the reductive component occurs, indicating a unidirectional
activity loss (0.75 vs. 0.55 nmol/minUmg in S9 and micro-
some fractions, respectively).
3.3. Glucocorticoid metabolism in whole cells
Whole cells were incubated under aerobic conditions with
di¡erent amounts of cortisone or cortisol. After extraction,
steroid analysis of the medium was performed. Whereas no
oxidation of cortisol to cortisone was observed, the reductive
reaction was carried out with 0.38 nmol cortisol formed per h
per 106 cells (Table 1), indicating steroid transport and me-
tabolism in intact recombinant yeast cells.
3.4. Substrate and inhibitor screening
A substrate screening was performed and kinetic constants
were determined (Table 2). Among the steroids tested, the
naturally occurring GCs (cortisol, cortisone, corticosterone
and 11-dehydrocorticosterone) turned out to be good sub-
strates as indicated by their intrinsic clearance (Vmax/km) val-
ues. Among the synthetic glucocorticoids, only the ring A
unsaturated GCs, prednisone and prednisolone, were metab-
olized by 11L-HSD. Further substitutions, like 9K-£uorination
or ring D modi¢cations as in dexamethasone, de£azacort and
budesonide, e⁄ciently prevented 11L-hydroxy dehydrogena-
tion. Bulky substituents at ring D also did not allow 11-oxo
reduction as demonstrated by the lack of product formation
in the case of 11-oxo budesonide.
The inhibitory e¡ect of synthetic steroids and other com-
pounds was evaluated on the cortisol oxidative and cortisone
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Table 1
Kinetic constants of recombinant human 11L-HSD-1 for 11L-dehydrogenase and 11-oxo reductase activities in whole P. pastoris cells, S9 frac-
tions, and microsomes from yeast and humans
Source 11L-HSD 11-oxo reduction
Km Vmax Km Vmax
Pichia pastoris
Whole cells ^ 0 n.d. 0.38 þ 0.1a
S9 9.2 þ 0.8 5.6 þ 0.2 1.9 þ 0.1 0.75 þ 0.1
Microsomes 10.3 þ 0.5 16.6 þ 0.2 2.5 þ 0.2 0.55 þ 0.2
Human liver
Microsomes 9.5 þ 0.5 2.2 þ 0.3 2.5 þ 0.1 0.07 þ 0.03
Substrates used were cortisol and cortisone for 11L-dehydrogenase and 11-oxo reductase activities, respectively. Km is given in Wmol/l, Vmax in nmol
product formed per min per mg protein. Values are given as mean þ S.D. aVmax given as nmol product per hour per 106 cells, incubated at 500 WM
steroid. Number of experiments: whole cells : n = 3; otherwise: n = 3^5. n.d.: not determined.
Table 2
Kinetic constants of recombinant human 11L-HSD-1 expressed in P. pastoris
Substrate Reaction Km Vmax Intrinsic clearance
Steroids
Cortisol d 9.2 þ 0.8 5.6 þ 0.2 0.60
Cortisone r 1.9 þ 0.1 0.75 þ 0.1 0.39
Corticosterone d 5.9 þ 0.3 1.06 þ 0.1 0.17
11-DHC r 1.7 þ 0.2 0.63 þ 0.1 0.37
Prednisolone d 25.7 þ 1.5 5.11 þ 0.2 0.19
Prednisone r 20.6 þ 1.4 1.38 þ 0.2 0.07
S9 preparations containing recombinant human 11L-HSD-1 were incubated with varying amounts of substrates in the presence of 1 mM coenzyme;
metabolite detection and quantitation was achieved by RP-HPLC. No background activities were observed in the parental mock-transformed
strain. Intrinsic clearance is de¢ned as Vmax/Km as apparent ¢rst order rate constant. Other synthetic glucocorticoids tested for 11L-hydroxysteroid
dehydrogenase or 11-oxo reductase activities include dexamethasone, budesonide, 11-oxo budesonide and de£azacort, however no activity was
detectable.
d: 11L-OH dehydrogenation; r : 11-oxo reduction. Number of experiments: n = 3^5.
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reductive activities of the recombinant enzyme (Table 3).
Strong inhibition (Ki6 2 Wmol/l) was observed with glycerrhi-
tinic acid (GA), its hemisuccinate ester carbenoxolone (CBX),
and the diuretic compound furosemide. Intermediate inhibi-
tion (2 Wmol/l6Ki6 100 Wmol/l) was observed with synthetic
steroids (dexamethasone, budesonide, de£azacort and stano-
zolol), and weak inhibition with the £avonoid naringenin,
which displayed comparatively high Ki values (350 and 327
Wmol/l for oxidation and reduction, respectively).
4. Discussion
Several investigations have established the importance of
the 11L-hydroxysteroid dehydrogenase system in the regula-
tion of corticosteroid hormone action, achieved by controlling
the access of ‘active’ cortisol to mineralocorticoid and gluco-
corticoid receptors [4,10,13^15]. Clear evidence has been ob-
tained for a crucial function of the type 2 enzyme (11L-HSD-
2) in mineralocorticoid receptor protection by oxidation of
glucocorticoids [10,16]. Recent experimental data suggest a
basic role for the type 1 enzyme in regenerating ‘active’ corti-
sol by reduction from cortisone, essential in glucocorticoid
functions such as hepatic carbohydrate metabolism and adi-
pose tissue fatty acid metabolism [13^15]. Analyses of homo-
zygous mice de¢cient in a functional type 1 11L-HSD gene
revealed resistance of these animals against hyperglycemia
provoked by stress or obesity [15]. Furthermore, 11L-HSD-1
expression in adipose tissues indicates a central position of
this enzyme in the pathogenesis of obesity, hypertension and
diabetes [13,14]. Thus, blockade by speci¢c inhibitors might
be advantageous in the pharmacological intervention towards
these diseases, a concept currently pursued.
Transient expression of 11L-HSD-1 in mammalian cell cul-
ture systems has been reported [9,17^20] with low speci¢c
activities. However, no successful bacterial, yeast or insect
cell overexpression of 11L-HSD-1 has been documented. To
allow studies on structure-function relationships of SDR hy-
droxysteroid dehydrogenases [6,21] we performed expression
of the human 11L-HSD-1 in the yeast P. pastoris and deter-
mined substrate speci¢cities and inhibitor constants using syn-
thetic and naturally occurring compounds.
Data obtained from our enzymological analyses veri¢ed
that the recombinant enzyme expresses kinetic constants con-
sistent with other data [17]. Recombinant human 11L-HSD-1
behaves in the yeast cellular environment as it does in mam-
malian systems (Table 1), i.e. when whole cells are incubated
only reductive activity is found [9,20]. Upon cell disruption,
the oxidative component is observed, exceeding the reductive
activity, which appears to be more labile than the oxidative
activity. Such a selective di¡erence in reaction direction of a
hydroxysteroid dehydrogenase is also consistent with the re-
sults of mutagenesis screenings, showing the critical depend-
ence of certain residues for the reaction direction [21].
Metabolism of synthetic glucocorticoids, clinically used for
immune suppression, is an important determinant of their
action. Depending on their chemical structure, they display
pharmacological pro¢les di¡erent from those of the naturally
occurring glucocorticoids. This can be explained in part by
their di¡erent metabolic properties, as for example in the
case of 9K-£uorinated GCs [22,23]. We therefore studied the
metabolism and inhibitor characteristics of commonly used
synthetic systemic and topical GCs with the recombinant
type 1 enzyme, allowing us to draw conclusions concerning
the active site architecture. Steroid ring A modi¢cations, such
as a double bond between C1 and C2 (prednisone, predniso-
lone), do not prevent catalysis. However, electronegative
groups, such as those from 9K-£uorination in dexamethasone,
block the dehydrogenase reaction. The reductase reaction,
however, possibly is not a¡ected either in type 1 or in type
2 11L-HSDs [24]. Bulky substituents in the vicinity of ring D,
e.g. 17,16-oxazole (de£azacort) or 16K,17K- propylmethylene-
acetal (budesonide), obstruct catalysis and these compounds
are no substrates for 11L-HSD-1. Importantly, the inhibition
constants of three compounds, budesonide, de£azacort and
GA, were signi¢cantly di¡erent concerning the reaction direc-
tion performed.
These novel ¢ndings suggest use of these substances in fur-
ther analysis of the three-dimensional structure and molecular
reaction mechanism of 11L-HSD-1. Naringenin, a £avonoid
ingredient of grapefruit juice, inhibits equally reductive and
oxidative components of 11L-HSD with Ki values in the WM
range, indicating that this compound probably binds with
weak a⁄nity to sites other than the steroid substrate, as ob-
served in other studies with various dehydrogenases and £a-
vone compounds [25,26]. Furosemide strongly inhibits both
reactions, in the same order of magnitude as GA in our assay,
indicating species and tissue di¡erences in inhibitor suscepti-
bility [26]. In conclusion, we achieved in this study expression
of native recombinant human 11L-HSD-1, demonstrated
properties of this protein, and investigated the inhibitor pro-
¢les of synthetic compounds with this medically important
enzyme.
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